IRADIMED CORPORATION ($IRMD)
Earnings Call Transcript · May 1, 2026
Highlights from the call
IRADIMED Corporation reported Q1 2026 revenue of $22 million, a 13% increase YoY, driven by strong performance across product lines, notably the MRI compatible IV infusion pump. Net income rose to $5.8 million or $0.45 per diluted share, a 22% increase over the prior year. Management highlighted the successful launch of the new 3870 MR IV pump, with ASPs exceeding expectations. The company maintained its full-year guidance, projecting revenue between $91 million and $96 million, and EPS of $1.90 to $2.05. The focus on the 3870 pump's replacement opportunity is expected to drive growth in the coming quarters.
Main topics
- Revenue Growth: Q1 2026 revenue increased by 13% YoY to $22 million, with strong contributions from the MRI compatible IV infusion pump and MR patient monitor. 'These results reflect solid execution across our product lines,' stated CEO Roger Susi.
- 3870 MR IV Pump Launch: The new 3870 MR IV pump's ASP is showing a lift closer to 20% over the historical 3860 pump ASP. Management is optimistic about the replacement opportunity, which will be a key growth driver for the next several years.
- Operating Income: Operating income increased by 33% YoY to $7.2 million, attributed to revenue growth and disciplined expense management.
- Gross Margin Improvement: Gross margin improved to 77% from 76% in Q1 2025, reflecting efficient cost management.
- Manufacturing and Supply Chain: Management is cautiously ramping up production of the 3870 pump, planning to increase output in the third and fourth quarters to meet demand.
Key metrics mentioned
- Revenue: $22 million (vs $19.5 million in Q1 2025, +13% YoY)
- Net Income: $5.8 million (+22% YoY)
- EPS: $0.45 (+22% YoY)
- Gross Margin: 77% (up from 76% in Q1 2025)
- Operating Income: $7.2 million (+33% YoY)
IRADIMED's Q1 2026 results and the successful launch of the 3870 pump position the company well for continued growth. The focus on replacement opportunities and higher ASPs could drive revenue, but manufacturing ramp-up and greenfield expansion remain areas to watch. Investors should monitor execution on production scale-up and market penetration of the new pump as key catalysts.
Earnings Call Speaker Segments
Operator
OperatorWelcome to IRADIMED Corporation's First Quarter of 2026 Financial Results Conference Call. [Operator Instructions] This call is being recorded today, May 1, 2026, and contains time-sensitive accurate information that is valid only for today. Earlier, IRADIMED released its financial results for the first quarter of 2026. A copy of this press release announcing the company's earnings is available under the heading News on their website at iradimed.com. A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov. This call is being broadcast live on the company's website at iradimed.com, and a replay will be available there for the next 90 days. Some of the information in today's session will constitute forward-looking statements with the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements focused on the future performance, results, plans and events and may include the company's expected future results. IRADIMED reminds you that future results may differ materially from these forward-looking statements due to several risk factors. For a description of the relevant risks and uncertainties that may affect the company's business, please see the Risk Factors section of the company's most recent reports filed with the Securities and Exchange Commission, which may be obtained free from the SEC's website at sec.gov. I want to turn the call over to Roger Susi, President and Chief Executive Officer of IRADIMED Corporation. Mr. Susi?
Roger Susi
ExecutivesThank you, operator, and good morning. Welcome to IRADIMED Q1 2026 earnings call. Sorry for a late start, we have a microphone problem. We withstand have a very rosy performance to announce with the first quarter 2026 revenue of $22 million, a 13% increase over the first quarter 2025. These results reflect solid execution across our product lines with strong revenue contribution of our MRI compatible IV infusion pump and our MR patient monitor noting that some revenue substantially drive from the [indiscernible]. There also continues to be growing revenue support for our ferromagnetic detection systems. Our continued revenue growth, combined with disciplined expense management, including a modified commission structure, drove operating income up $7.2 million, a 33% improvement over the first quarter of 2025 with net income of $5.8 million or $0.45 per diluted share, a 22% increase over the prior year. Next, I'd like to provide a brief recap of our expectations for the new 3870 MR IV pump. Recalling that in positioning this new product and its pricing, we have anticipated that the 3870 pump [indiscernible] would increase by some 10% to 14% over the historical 3860 pump ASP. However, they'll just beginning. Initial quoting and actual orders are showing a lift closer to 20% for the 3870 ASP. Additionally, we are seeing that a majority of this new business is for Quad for pump systems rather than simply replacing the older 3860 Doble channel system. Thus, we are seeing both a higher per pop ASP and a larger group of customers purchasing twice as many pump channels, doubling the number of pump channels at a particular customer site. Though obviously, our sales efforts are in the very stages. These 2 factors present a most exciting prospect for bookings and revenue as the year progresses. Opportunities for their 3870 pump system, as previously described, are both increased penetration on the greenfield which are predominantly those facilities that continue to deal with IV fluid delivery in the MR setting via various full school workarounds as well as the quite substantial replacement of imatinib aged installed base of 3860 pump systems. The most immediate and significant increase coming from the large replacement opportunity. This replacement opportunity will be our key growth driver for the next several years. As that growth, as mentioned, has now begun to be in the driving factor in this second quarter. To provide some clarity to the revenue expectations in Q2 and beyond, it will not be a step change, but rather a controlled rank. which is initially controlled -- composed of declining revenue derived from the older 3860 pump system, domestic orders, which have trailed off as expected, offset positively by increasing revenue from the new 3870 system as we ramp up its production. And Jim, our CFO, will provide our Q2 guidance for further quantifying how Q2 is expected to develop. To reiterate, source of the 3870 opportunity is given in our previous. For the U.S. market, there are approximately 6,400 5-plus year over 3860, 3861 pump channels up for replacement. We have been selling approximately 1,100 such 3860 channels annually. With the new 3870, we are targeting adding another 1,000 channels per year through replacement sales from the existing 6400 3860 units that are over 5 years old. As advertised, this starts in Q2 and continues through the rest of 2026 and beyond. It is also important to understand that replacing only 1,000 channels per year, leaves many thousands more or be replaced in the years to come. For our domestic business on selling north of 2,000, 3870 pump channel [indiscernible] with the higher ASP currently being experienced. We expect to approach a $50 million annual revenue run rate [indiscernible] adding disposable maintenance, international sales, the MR monitoring business, prefer magnetic system, one can understand our confidence in achieving a 100-plus revenue run rate as 2026 progresses. Timing has been discussed previously as well. But to recap that, we did not launch our sales effort for 3870 until late January. As advised, we targeted shipping 130 to 135, 3870 in Q2. Both the launch and the manufacturer of those initial 130, 135, 3870s are progressing as planned. As we issued in this morning's press release, the interest in the new 3870 has been gratified. The number of orders and dollar size, well ahead of our expectations this early in the product launch. Given this great curve, still, however, Q2 revenue will not fully reflect this high level of exciting order activity as shipping even 135 new 3870 systems combined with the declining revenue of over 3860s keeps Q2 revenue somewhat in check. Again, it will be the back half of 2026 that was shy. As we continue to book more comps, at a higher ASP and fixing production of this 3870. I'll turn the call over to Jack Glenn, our CFO, to review the quarter's financial results and provide deeper color on growth through the balance of the year. Jack?
John Glenn
ExecutivesThank you, Roger, and good morning, everyone. As in the past, our results are reported on a GAAP basis and a non-GAAP basis. You can find a description of our non-GAAP measures in this morning's earnings release and a reconciliation to GAAP on the last page. For the three months ended March 31, 2026, revenue was $22 million, up 13% from $19.5 million in the first quarter of 2025. IV Infusion Pump Systems contributed $7.7 million, up 28% year-over-year, reflecting the fulfillment of 3860 pump backlog from the beginning of the year. Patient bioclin Fonti systems contributed $7.1 million, up 9% year-over-year. Disposable revenue was $4.9 million, consistent with the prior year period, while ferromagnetic detection systems contributed $600,000. Domestic sales accounted for 82% of total revenue, consistent with the first quarter of 2025. Gross profit for the quarter was $16.8 million with a gross margin of 77%, up from 76% in the first quarter of 2025. Total operating expenses for the quarter were $9.6 million, roughly in line with the first quarter of 2025. General and administrative expenses were $4.6 million. Sales and marketing were $4.1 million and research and development were $1.1 million. The increase in R&D was largely due to the end of capitalized internally developed software for the 3870 compared with Q1 of 2025 as well as new product development for the next-generation line. Income from operations for the quarter was $7.2 million. Net income was $5.8 million or $0.45 per diluted share on GAAP basis, a 22% increase over the prior year period. Non-GAAP net income was $6.4 million or $0.49 per diluted share, up 17%. The effective tax rate for the quarter was approximately 25%. The increase in the effective tax rate for the quarter was largely due to the timing of deductions tied to the Windfall deduction for equity grants, which is a discrete item taken at the time of vesting of the equity brands, most of which will occur in the fourth quarter of this year. Therefore, we anticipate that the rate will trend down by the end of the year be more in line with previous years. We ended the quarter with cash and cash equivalents of $56.4 million. Cash flows from operations was $8.3 million for the quarter compared to $4.3 million in the first quarter of 2025, an increase of 93%, reflecting higher net income and favorable working capital movements. Non-GAAP free cash flow was $7.6 million for the quarter after capital expenditures of approximately $500,000. Also today, the company's Board of Directors declared a regular quarterly cash dividend of $0.20 per share on outstanding common stock payable on May 29, 2026, to stockholders of record as of the close of business on May 15, 2026. And lastly, for our financial guidance. For the second quarter of 2026, we expect revenue of $20 million to $21 million. GAAP diluted earnings per share of $0.40 to $0.44 and non-GAAP diluted earnings per share of $0.44 to $0.48. For the full year 2026, we reaffirm our guidance with a revenue of $91 million to $96 million, GAAP diluted earnings per share of $1.90 to $2.05 and non-GAAP diluted earnings per share of $2.06 to $2.21. The company expects stock-based comp exchange expense net of tax to be approximately $2.4 million for the full year and $600,000 for the second quarter of 2026. With that, I will turn the call over to questions. Operator?
Operator
Operator[Operator Instructions] Our first question comes from Frank Takkinen with Lake Street Capital Markets. .
Frank Takkinen
AnalystsAnd congrats on all the solid progress. I was hoping to start with a follow-up on Roger, your comments related to quad system ordering. How do you -- maybe break that down a little bit why you think folks are going from a single dual channel to ordering for individual channels. And then my assumption is you can't assume everybody goes to ordering 4 channels. But is there something specific to call out with some of these early customers that would be more likely to order 4 systems? Or is it fair to assume that a lot of your customers reordering could fall into this camp of ordering quad system channel?.
Roger Susi
ExecutivesYes, good question, Frank. Well, yes, that's a good question. So it's a bit of a surprise that sold -- yes, more than half of these orders have been taken so far and in that is quad system, so that's a bit surprising. We were hoping for maybe 10% and 15% customers, we could step up to this doubling the number of channels they operate. So why? Your question, I guess, is why they have it? So I have to say that I'm going to give the sales force a little credit for this by and large. They are close to the customers. And they felt that with the new system, the way it works and the way the impression on me customers well, it's smaller than the old pump. And the way they actually step together on a poll that they really work together as 4 very easy. And so we're showing it that way. We show -- we walk in and we're showing the Quad stack. And when customers see it, though they, of course, I've been thinking in terms of that before because they only had 2 channel [indiscernible] before. It does seem that it's fairly -- is fairly quick that, as I said, more than happy these pretty suggesting customers fairly quickly see that oh, wow, we've had -- we've had some cases come up over the years to give us in the older and pump where, yes, we needed a third and a fourth channel handy. And this sort of stimulates this conversation to make customers think of those situations where they consider they needed that many channels. And they put the budget through and and another very positive sign has been -- these orders get -- we really started [ slowing ] in late January, as I pointed out. So orders that we're getting in at this point have been rather quick -- quicker than the typical cycle time for any more so far. So it's all very positive. But I think that's generally the reason if you picked it out that customers do have experience where after channels were required in the past, and there they go on it and taking advantage quad staff.
Frank Takkinen
AnalystsThat's great. And then maybe just one follow-up on that. Is there a financial element to it as well? Are they getting a better per pump deal if they're buying 4 at a time....
Roger Susi
ExecutivesNo. That's not the -- pump is, as I said, was high. the net price of the previous pump was 20,000. So let's [indiscernible], right? So the greater spot was 20,000. You can buy the second channel providing to 10. So as we've told many times, our typical ASP pump deal -- it's just under 4 by the time you get the [indiscernible] and all that and the remote and all that. That's where it was landing. So the quad system we've been selling again quad staff, again, 3870 the IV pole remote control, these are coming in at more than 100,000. So it's very exciting.
Frank Takkinen
AnalystsWell, that's great. Maybe a bigger picture question. The concept that you laid out from going from around 1,000. I think you said 1,100 pumps a year to adding another incremental 1,000 on top of that. What are the drivers to that? I assume this concept, we just talked about the quad pump ordering is a significant driver, too. But is there an assumption of greenfield capture in that number as well? Or is it really just replacement?
Roger Susi
ExecutivesNo. No. What I was speaking about that earlier in the call, I'm just talking taking 1,000 out of the installed base where the old pumps are refill would be extra. And frankly, maybe I probably more clear, but frankly, the excitement well and the customers -- existing customers calling us [indiscernible] see the new pump is it kind of a fancy right now. I don't see that we're going to have time to start calling on the greenfield for a while. So no, that doesn't have any upside from greenfield factored in at this point.
Frank Takkinen
AnalystsThat's great. And then just last one for me, and I appreciate all the time on manufacturing. How are you feeling from that standpoint? I think in our previous conversations, you felt really good about that. But as you're taking orders now and scaling that, how is all that going?
Roger Susi
ExecutivesWell, sales team wants us to ramp it up a lot faster. But we're trying to take it a bit cautiously and ramp it up here, that's why I'm talking about 130, 135 pumps for this quarter. The sales team would like us to ship over 200, but we just can't do it. We're going to stay at that low. We're going to get them right. And then third quarter, we'll plan to near double that up again over -- in the next quarter, maybe a little bit more in third quarter. and so on in the fourth quarter, where we should be by fourth quarter is a pretty heavy stride on the number of the new pumps that we're kicking out of here. And of course, having this new facility, we got the space and, yes, it's a matter of ramping up to [indiscernible] and stabilizing the supply chain. And so that's why we've been a little conservative on the ramp.
Operator
Operator[Operator Instructions] I'm showing no further questions at this time. I'd like to turn the call back over to Roger Susi for closing remarks.
Roger Susi
ExecutivesWell, thank you all once again for joining us on today's call. I'd like to add as we close the call today, that the market is very excited about the new 3870 pump system, and we are being invited into customer facilities to show the device at a very high rate and the sales team is rather than on date. Further, we have had bookings with greater-than-expected ASP as well as if the majority of those were thus far are for double the number of pump channels. So it's clear to us that the 3870 is having a great acceptance, generates great excitement and motivated very positive and rather quick customer response. So we're quite pleased. And with that, I look forward to demonstrating rather success, as we further execute the launch of the exciting 3870 MRI up system and capitalize on the huge replacement opportunity throughout 2026 and beyond. Thank you.
Operator
OperatorThank you. This concludes the call. You may now disconnect.
For developers and AI pipelines
Programmatic access to IRADIMED CORPORATION earnings transcripts and 32,000+ others is available through the
EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.